Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.67 |
| ▸ | DRD3 | P35462 | 8/20 | 0.67 |
| ▸ | HTR1A | P08908 | 7/20 | 0.67 |
| ▸ | HTR7 | P34969 | 5/20 | 0.67 |
| ▸ | HTR2A | P28223 | 5/20 | 0.67 |
| ▸ | DRD4 | P21917 | 4/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | QPCT | Q16769 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519839 | 0.92 | DRD2 (0.63) | DRD2DRD3HTR1AHTR7HTR2A | |
| Fumaric Acid SCHEMBL7528661 | 0.91 | DRD2 (0.60) | DRD2DRD3HTR1AHTR7HTR2A | |
| Fumaric Acid SCHEMBL7528654 | 0.91 | DRD2 (0.60) | DRD2DRD3HTR1AHTR7HTR2A | |
| SCHEMBL7520750 | 0.89 | DRD2 (0.54) | DRD2DRD3HTR1AHTR7HTR2A | |
| Fumaric Acid SCHEMBL7528644 | 0.83 | HTR1A (0.56) | DRD2DRD3HTR1AHTR7HTR2A | |
| Fumaric Acid SCHEMBL7528638 | 0.83 | HTR1A (0.56) | DRD2DRD3HTR1AHTR7HTR2A | |
| SCHEMBL5185969 | 0.83 | DRD2 (0.59) | DRD2DRD3HTR1AHTR7HTR2A | |
| SCHEMBL491920 | 0.82 | SMN1; SMN2 (0.60) | QPCTTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7520064 | 0.81 | DRD2 (0.50) | DRD2DRD3HTR1AHTR7HTR2A | |
| SCHEMBL7519088 | 0.81 | DRD2 (0.50) | DRD2DRD3HTR1AHTR7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | claimed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | claimed |
| EP-1117663-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018767-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-06 | — | — | WO | claimed |
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
| EP-1117663-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018767-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | DRD2 8/4885DRD3 13/4885HTR1A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.